DE69132717T2 - Hepatitis-a-impfstoff - Google Patents

Hepatitis-a-impfstoff

Info

Publication number
DE69132717T2
DE69132717T2 DE69132717T DE69132717T DE69132717T2 DE 69132717 T2 DE69132717 T2 DE 69132717T2 DE 69132717 T DE69132717 T DE 69132717T DE 69132717 T DE69132717 T DE 69132717T DE 69132717 T2 DE69132717 T2 DE 69132717T2
Authority
DE
Germany
Prior art keywords
virus
pct
hepatitis
polypeptide
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69132717T
Other languages
English (en)
Other versions
DE69132717D1 (en
Inventor
Christopher Thomas
Peter Karayiannis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial College of Science Technology and Medicine
Original Assignee
Imperial College of Science Technology and Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College of Science Technology and Medicine filed Critical Imperial College of Science Technology and Medicine
Publication of DE69132717D1 publication Critical patent/DE69132717D1/de
Application granted granted Critical
Publication of DE69132717T2 publication Critical patent/DE69132717T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Valve Device For Special Equipments (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)
  • Glass Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
DE69132717T 1990-02-02 1991-02-04 Hepatitis-a-impfstoff Expired - Fee Related DE69132717T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909002387A GB9002387D0 (en) 1990-02-02 1990-02-02 Improvements relating to the prevention of hepatitis
PCT/GB1991/000163 WO1991011460A1 (en) 1990-02-02 1991-02-04 Hepatitis a vaccines

Publications (2)

Publication Number Publication Date
DE69132717D1 DE69132717D1 (en) 2001-10-11
DE69132717T2 true DE69132717T2 (de) 2002-07-04

Family

ID=10670339

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69132717T Expired - Fee Related DE69132717T2 (de) 1990-02-02 1991-02-04 Hepatitis-a-impfstoff

Country Status (9)

Country Link
US (1) US5605692A (de)
EP (1) EP0513090B1 (de)
JP (1) JP3086250B2 (de)
AT (1) ATE205220T1 (de)
CA (1) CA2072982C (de)
DE (1) DE69132717T2 (de)
ES (1) ES2165840T3 (de)
GB (1) GB9002387D0 (de)
WO (1) WO1991011460A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506419A (ja) * 1996-04-19 2002-02-26 アメリカ合衆国 Ａ型肝炎ウイルスポリタンパク質の抗原反応性領域
US6368602B1 (en) * 2000-06-16 2002-04-09 Hadasit Medical Research Services And Development Ltd Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine
WO2009032913A2 (en) 2007-09-04 2009-03-12 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Thermal inactivation of rotavirus
CN103923882B (zh) * 2013-08-09 2016-09-28 北京科兴生物制品有限公司 甲肝病毒单克隆抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4614793A (en) * 1983-10-14 1986-09-30 Merck & Co., Inc. Hepatitis A--subunit antigen
DE3582812D1 (de) * 1984-03-02 1991-06-20 Merck & Co Inc Dns-fragmente welche fuer peptide kodieren, die faehig sind in vivo die synthese von antihepatitis-a-virus-antikoerpern zu induzieren.
SU1469856A1 (ru) * 1986-07-31 1990-09-30 Институт биоорганической химии им.М.М.Шемякина Способ конструировани рекомбинантной плазмидной ДНК, кодирующей синтез полипептидных субстанций против гепатита А

Also Published As

Publication number Publication date
ES2165840T3 (es) 2002-04-01
JP3086250B2 (ja) 2000-09-11
DE69132717D1 (en) 2001-10-11
WO1991011460A1 (en) 1991-08-08
EP0513090B1 (de) 2001-09-05
CA2072982C (en) 1999-09-07
US5605692A (en) 1997-02-25
ATE205220T1 (de) 2001-09-15
JPH05503524A (ja) 1993-06-10
GB9002387D0 (en) 1990-04-04
CA2072982A1 (en) 1991-08-03
EP0513090A1 (de) 1992-11-19

Similar Documents

Publication Publication Date Title
PT992580E (pt) Epitopos para celulas t humanas imunodominantes do virus da hepatite c
ATE141946T1 (de) Hiv-2-virusvarianten
BR9708401A (pt) Vetores de vìrus de para-varìola
ZA936970B (en) Anti-feline immunodeficiency virus (FIV) vaccines
ATE205220T1 (de) Hepatitis-a-impfstoff
ATE104349T1 (de) Vakzine gegen coccidiose.
ES2061603T3 (es) Mutantes viricos de la rinotraqueitis bovina infecciosa, vacunas que los contienen, metodos para la produccion de los mismos y metodos para el empleo de los mismos.
CY2540B1 (en) Vaccine against mumps containing a jeryl-lynn virus strain
DE68920502T2 (de) Pseudorabiesvirus-Impfstoff.
MY107451A (en) Cloning and expression of a rhoptry associated protein of p.falciparum
FI902814A0 (fi) Proteiner, vaccin och nukleinsyror.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee